137 results about "MicroRNA" patented technology

The present invention relates to a formulation comprising an oligonucleotide drug which is an antagonist of microRNA-21 as an active agent for administration to a human subject in need thereof by inhalation.

This invention belongs to the field of immunoassay and biosensing technology, and discloses a method for preparing a ratiometric ECL biosensor based on Eu / Tb-Lu MOGs. Using Eu / Tb-Lu MOGs as the luminescent material and H3-tctpy and luminol as ligands, a single-luminescent material with dual ECL emission is synthesized. Lanthanide ions provide the cathode ECL emission, enhanced by the antenna effect and Tb→Eu energy transfer; the anode emits light from luminol using dissolved oxygen in water, requiring only the addition of K2S2O8 as a single co-reactant, resulting in fewer side reactions and a stable signal. The dual-potential ratiometric sensing utilizes the dual ECL signal for self-calibration, improving anti-interference and reliability; the single-luminescent dual-potential system achieves synchronous anode / cathode luminescence, simplifying the system and improving detection accuracy. By detecting changes in the ECL signal of different concentrations of analytes, the detection of microRNA-126 is achieved.

The present application describes miRNAs in the diagnosis and treatment of small fiber neuropathy (SFN).

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

This invention discloses a microRNA-responsive 1,2-dioxane-based chemiluminescent compound, its dual-probe system, kit, synthesis method, and applications. The compound's core is an o-acrylate-substituted phenoxyadamantane-1,2-dioxane, with the phenolic hydroxyl group protected by an azide benzyl group. The two-component probe system constructed based on this compound comprises an azide-modified first probe and a phosphine-modified second probe, each complementary to different segments of the target microRNA. Hybridization brings the two probes closer, triggering a Staudinger reaction to remove the protecting group and activate the chemiluminescent signal. This probe system requires no enzyme amplification or nucleic acid extraction, achieves a detection limit of 1.37 fM, and a signal-to-noise ratio as high as 157-fold. It can be successfully used for real-time imaging of endogenous microRNA-21 in live cells, showing broad application prospects in early tumor screening, auxiliary diagnosis, and prognostic assessment.

Provided are microRNA from a Rhodiola root and uses thereof in the prevention and / or the treatment of a fibroplasia medical sign and / or syndrome.

The invention discloses a microRNA (Ribonucleic Acid) response type 1, 2-dioxetane chemiluminescent compound as well as a double-probe system, a kit, a synthesis method and application thereof. The parent nucleus of the compound is o-acrylate substituted phenoxy adamantane-1, 2-dioxetane, and a phenolic hydroxyl group is protected by an azido benzyl group. A two-component probe system constructed based on the compound comprises a first azide-modified probe and a second phosphino-modified probe, the first azide-modified probe and the second phosphino-modified probe are respectively complementary with different sections of target microRNA, the two probes are pulled close through hybridization, a schudinger reaction is triggered to remove a protecting group, and a chemiluminescence signal is activated. The probe system does not need enzyme amplification and nucleic acid extraction, the detection limit reaches 1.37 fM, the signal-to-noise ratio reaches up to 157 times, and the probe system can be successfully used for real-time imaging of living cell endogenous microRNA-21 and has wide application prospects in the fields of early tumor screening, auxiliary diagnosis and prognosis evaluation.

Senescent cells are implicated in aspects of age-related decline in health and may contribute to certain diseases. Embodiments include formulations and methods for promoting longevity and treating a senescence associated disease or disorder. Applicants present three distinct classes and multiple associated therapeutic molecules that can function alone or in combination with the other molecules. The classes include transcription regulators, lipid intermediates and microRNAs. Additional embodiments include methods of promoting longevity by administering GRAS substances.

The present invention relates to a microRNA-responsive multi-gene editing system, and specifically, to: a multi-gene editing system; a polynucleotide encoding the multi-gene editing system; a recombinant vector comprising the polynucleotide; a transformant into which the recombinant vector is introduced; a gene editing composition comprising the polynucleotide; and a pharmaceutical composition for treating or preventing cancer, the composition comprising the gene editing composition. The gene editing system according to the present invention has the advantage of being able to be used in gene therapy applications on the basis of high specificity and safety.

The invention pertains to a therapeutic formulation, CARDIOGARDIA, for the management of cardiac arrest. The formulation co-formulates selected microRNAs, including miR-21, miR-1, miR-29, miR-17, and miR-133, and antithrombin and essential electrolytes in a single formulation. The different components in combination target various pathological processes associated with cardiac arrest, including fibrosis, apoptosis, arrhythmia, and coagulopathy. Delivery may be affected by suitable pharmaceutical vehicles or carriers to enable effective delivery. By acting on these distinct pathological processes in combination, the formulation provides a multifaceted approach to stabilizing cardiac function and improving resuscitation outcome. The invention further encompasses methods of treating subjects experiencing cardiac arrest by administering the formulation in therapeutically effective amounts.

One aspect relates to: a marker composition for diagnosis or prognosis of Alzheimer's disease, comprising microRNA-214 (miRNA-214); a marker composition for diagnosis or prognosis of Alzheimer's disease, comprising an agent for measuring an expression level of miRNA-214; a diagnostic or prognostic kit; and a method for providing information for diagnosis or prognosis. According to one aspect, data analysis for the diagnosis of Alzheimer's disease can be made to measure the expression level of miRNA-214 in blood, and as a biomarker for the prognosis of Alzheimer's disease, the microRNA can be advantageously used to predict the progression rate and treatment result of diseases.

The invention discloses preparation of a paper-based DNA (deoxyribonucleic acid) hydrogel electrochemical luminescence sensor and application of the paper-based DNA hydrogel electrochemical luminescence sensor in microRNA (ribonucleic acid) detection. Hydrophilic and hydrophobic patterns are printed on chromatographic paper, a three-electrode system is subjected to silk-screen printing, AuPd nano particles are modified on a detection layer to serve as a co-reaction accelerant, DNA hydrogel is loaded on the detection layer, hybridization chain reaction is started by means of specificity of a target object, Cas12a is activated, the DNA hydrogel is broken, the electrochemical luminescence intensity is changed, and sensitive detection of microRNA is achieved.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

A method for generating anti-tumor macrophages deriving from monocytes and monocytic myeloid-derived suppressor cells (M-MDSCs) using miRNA modulators is described. Compositions and methods for treating cancer, autoimmune disease, and inflammatory conditions using such cells are also described.

A method for the precise cellular destruction of an oncogenic non-coding RNA with a RNA-binding small molecule conjugated with bleomycin A5 is described. The method affords reversal of phenotype. Bleomycin A5 was coupled to an RNA-binding molecule that selectively binds the microRNA-96 hairpin precursor (pri-miR-96). By coupling of bleomycin A5's free amine to the RNA-binding molecule, its affinity for binding to pri-miR-96 is >100-fold stronger than to DNA. The conjugate compound selectively cleaves pri-miR-96 in triple negative breast cancer (TNBC) cells. Selective cleavage of pri-miR-96 enhances expression of FOXO1 protein, a pro-apoptotic transcription factor that miR-96 silences, and triggers apoptosis in TNBC cells. No effects were observed in healthy breast epithelial cells. This method provides programmable control for targeting RNA through the selection of an RNA-binding molecule / bleomycin A5 conjugate and provides a facile method of mapping the cellular binding sites of an RNA-binding molecule.

The invention relates to the field of gene therapy. In addition the invention relates to the field of interfering RNA and / or microRNA (miRNA). In particular the invention relates to gene therapy involving such miRNA's and more in particular to methods and means to improve delivery of said miRNAs to target cells of a patient. The invention provides for a gene delivery vehicle for use in delivery of a miRNA to a cell resulting in silencing of a desired gene and whereby spread of said miRNA to other non-transduced cells results in silencing of said desired gene in said non-transduced cells.

The application discloses a method for detecting microRNA-21 by photothermal analysis. The method mixes lock-step chain functionalized gold nanoparticles, substrate chain functionalized gold nanoparticles, microRNA-21, divalent aqueous manganese salt and water to generate HRP; H2S is generated by the reaction of thiosulfate and hydrogen peroxide catalyzed by HRP, and then the etching of Prussian blue by H2S affects the photothermal performance of Prussian blue, thereby constructing the linear relationship between the concentration of microRNA-21 and temperature, and realizing the signal detection of the target microRNA-21. The method ingeniously combines the PB with the 3DDNA Walker-based signal amplification, greatly improves the sensitivity, and realizes the low-concentration and high-selectivity detection of the target.

The present invention relates to: a biosensor for simultaneous multiplex detection of target nucleic acid molecules, the biosensor comprising gold nanorods with immobilized ssDNA and ssRNA; and a composition for diagnosing cancer using the biosensor. The present invention enables rapid simultaneous multiplex detection of cancer-associated cfDNA and miRNA, which are target nucleic acid molecules, to be performed with high accuracy and sensitivity, and thus can be advantageously used in the field of cancer diagnosis.

The present invention relates to compositions and methods for treating cancer utilizing oncolytic viruses, components thereof, and / or derivatives thereof. In particular, the present invention relates to modified picornaviruses that contain alterations in one or more of their capsid proteins that confer enhanced binding ability to cancer cells.

Use of at least one microRNA comprising a nucleotide sequence set forth in any of SEQ ID NOS: 1 to 15 in a biological sample derived from a subject as a pancreatic cancer biomarker, wherein the pancreatic cancer biomarker is for determining whether the subject suffers from pancreatic cancer, for determining a pathological condition of the subject suffering or suffered from pancreatic cancer, or for identifying a test substance capable of treating pancreatic cancer.

The invention relates to the technical field of biological medicines, in particular to application of four micro RNAs (Ribonucleic Acid) of miR-92a, miR-25, miR-30d and miR-30c and inhibitors targeting the four micro RNAs to preparation of medicines for resisting metastasis of multiple cancer species such as breast cancer, colorectal cancer and melanoma. When the nucleic acid inhibitor anti-agomirs targeting at least one of a set consisting of miR-92a, miR-25, miR-30d and miR-30c is used for treating metastasis of multiple cancer species, the anti-metastasis effect is remarkable, the universality is high, and the nucleic acid inhibitor anti-agomirs can show a strong inhibition effect in three different tumor metastasis models of breast cancer, colorectal cancer and melanoma; especially, when the four inhibitors are combined for use, the synergistic effect is prominent, the colorectal cancer liver metastasis load can be reduced by 90% or above, the breast cancer metastasis rate is reduced by 80% or above, the melanoma metastasis inhibition rate is 65% or above, and the composition is suitable for treatment of multi-cancer metastasis.

The present invention relates to a novel microRNA for in vitro early diagnosis of mild cognitive impairment and Alzheimer's dementia, and a convergence diagnostic cartridge and diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained by molecular analysis exhibits differences in expression levels in the plasma of a normal group, a mild cognitive impairment patient group, and an Alzheimer's dementia patient group, and has the effect of reducing the expression levels of mild cognitive impairment- and Alzheimer's dementia-related proteins. Therefore, by using a novel miRNA present in plasma as a molecular diagnostic index in a non-invasive manner, the present invention enables not only early diagnosis of Alzheimer's dementia but also screening for mild cognitive impairment and Alzheimer's dementia.

The present invention is in the field of biomedicine and drug delivery as well as pest and vector control. The present invention relates to a novel family of silicon-introduced ionizable cationic lipids belonging to the trademark LipexSill second generation lipids wherein the tail is linked to the head group via a biodegradable silicon-based acetal linker. Lipids containing a silicon-based acetal linker are the most advanced, and are effective as ionizable cationic lipids in formulating empty or loaded lipid nanoparticles (LNPs). The novel linker according to the present invention is [WO2022129966] designed using a proprietary borane catalyst. The present invention describes the synthesis of lipids of formula (I), the formation and characterization of nanoparticles, and biological experiments that prove that lipid nanoparticles prepared with these novel lipids can effectively deliver their cargo receptors (cargo) (e.g., RNA, DNA, mRNA, siRNA, dsRNA, pDNA, microRNA, circular DNA, small bioactive molecules) into cells.

FIELD: urology; oncology.SUBSTANCE: used to diagnose the form of bladder cancer in patients with urothelial carcinoma. Tumor tissue is collected. The expression levels of microRNA miR-26b, miR-146b, miR-183 are determined. The obtained values are substituted into the formula for calculating the probability of muscle-invasive bladder cancer (U). If the Y value is above 0.5, muscle-invasive bladder cancer is diagnosed. If the Y value is equal to or lower than 0.5, non-muscle-invasive cancer is diagnosed.EFFECT: method improves the diagnostic accuracy by assessing the expression level of miR-26b, miR-146b, and miR-183.1 cl, 2 ex

The invention provides oligonucleotide and / or oligonucleotide analogue molecules that are antagonists of a microRNA, preferably antagonists of human microRNAs hsa-miR-23b-3p and hsa-miR-218-5p, that comprise a mixture of phosphorothioate and phosphodiester linkages, and that are conjugated to at least one oleic acid molecule. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and / or MBNL2. The present invention further provides compositions comprising said oligonucleotides and / or oligonucleotide analogue molecules and their uses for the treatment and prevention of DM in a subject in need thereof.

The present invention provides nucleic acid molecules and methods that use miRNA sequences that knocking down mRNA for the human DNA mismatch repair protein MutS Homolog 3 (MSH3), thereby resulting in the treatment of Huntington's Disease.

The invention discloses a microRNA (Ribonucleic Acid) response type xanthene-hemicyanine fluorescent dye as well as a two-component probe system, a synthesis method and application thereof. The structure of the fluorescent dye is shown as a general formula I, and the fluorescent dye can be connected with a targeting ligand (such as short-chain RNA) through carboxyl. The two-component probe system is composed of two short-chain RNAs which are respectively connected with the dye and a biological orthogonal reaction partner (such as tetrazine), a biological orthogonal reaction is triggered through target microRNA-21 mediated hybridization, and the near-infrared fluorescence and photosensitive activity of the dye are specifically activated. The dye and the probe system can realize fluorescence imaging with high signal-to-noise ratio for overexpressed microRNA-21 in tumors, and generate active oxygen under laser irradiation for photodynamic therapy, thereby realizing integration of diagnosis and treatment. The dye and the probe system provided by the invention have the advantages of high biological safety, simplicity and convenience in preparation, high specificity and the like, and have wide application prospects in early diagnosis and treatment of malignant tumors.

The invention relates to the technical field of molecular biology and medical detection, and particularly discloses a group of gallbladder cancer plasma exosome microRNAs markers as well as a detection method and application of the gallbladder cancer plasma exosome microRNAs markers, and the markers comprise at least one of miR-135b-5p, miR-224-5p, miR-451a, miR-148a-3p and miR-375-3p. The marker combination shows a characteristic expression profile (two-liter and three-drop) in gallbladder cancer patients; the invention provides a non-diagnostic purpose detection method of the marker, efficient and non-invasive identification of gallbladder cancer is realized by optimizing an exosome separation and detection process and constructing a combined diagnosis model, the AUC reaches 0.987, the sensitivity is 93.3%, and the specificity is 91.7%; the marker and the method can be used for preparing a detection kit related to gallbladder cancer, and have important clinical application value.